Home

Harlan Waksal

CIK 1449008 · Executive Chair · last filed 2024-12-11

Harlan Waksal is an Executive Chair who has filed 52 SEC Form 4 insider transactions across 3 companies since 2009. Across all open-market trades the lifetime net is +$1.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $4.9M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$4.88M

Companies

3

Total Filings

52

Lifetime Open-Market Net

$1.48M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Lyra Therapeutics, Inc. (LYRA) Delisted Executive Chair 10,739 $0.70 $7.5K $1.07M 7 2024-12-11
Kadmon Holdings, Inc. (KDMN) Delisted President, CEO 0 $9.50 $0 $143.0K 18 2021-11-09
SNT Director 2,805,750 $1.74 $4.88M $263.5K 18 2012-11-16

Recent Filings

52 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-04-25 — Notice (144) −145,370 -$14.9K EDGAR
2024-12-11 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2024-03-20 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) +275,000 $0 EDGAR
2023-11-13 Lyra Therapeutics, Inc. (LYRA) Delisted Buy (P) +25,000 $74.1K EDGAR
2023-02-02 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2022-06-21 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2022-04-13 Lyra Therapeutics, Inc. (LYRA) Delisted Buy (P) +236,966 $1000.0K EDGAR
2022-02-18 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2021-11-09 Kadmon Holdings, Inc. (KDMN) Delisted Disp (D) −177,945 -$1.69M EDGAR
2021-05-17 Kadmon Holdings, Inc. (KDMN) Delisted Grant (A) +25,000 $89.0K EDGAR
Showing 1–10 of 52
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.